VITAC : étude multicentrique randomisée évaluant l’efficacité du tacrolimus pommade 0,1 % versus placebo dans le vitiligo non-segmentaire du visage de l’adulte

Duplaine, Alexandra; Andreu, Nicolas; Maillard, H.; Droitcourt, Catherine; Passeron, Thierry; Sénéschal, Julien; Ezzedine, Khaled

doi:10.1016/j.annder.2020.09.089

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Twenty‐five trials were identified of which 21 reported repigmentation rates that could be categorized in at least one of the different categories (0%, 0%–25%, 25%–50%, 50%–75%, 75%–100%) (Abdel‐Fattah et al, 1982; Anbar et al, 2015; Dawid et al, 2006; Diehl et al, 2021; Duplaine et al, 2020; Ezzedine et al, 2022; Farajzadeh et al, 2009; Goren et al, 2014; Hartmann et al, 2008; Ho et al, 2011; Jalali et al, 2012; Jalalmanesh et al, 2022; Karuppusamy et al, 2022; Lubaki et al, 2010; Naini et al, 2012; Nowroozpoor Dailami et al, 2020; Orecchia & Perfetti, 1992; Parsad et al, 2003; Radakovic et al, 2009; Rodríguez‐Martín et al, 2009; Rosmarin et al, 2020, 2022; Seneschal et al, 2021; Vanderweil et al, 2017). Twelve trials mentioned the mean/median difference in the affected vitiligo area between baseline and follow‐up.…”

Section: Resultsmentioning

confidence: 99%

A meta‐analysis of the placebo response in vitiligo: Causes and consequences for the interpretation of clinical trials

Speeckaert,

van Geel

2023

Pigment Cell Melanoma Res

View full text Add to dashboard Cite

The current understanding of the placebo response in vitiligo is limited. Nonetheless, it is difficult to compare the outcomes of vitiligo trials if the repigmentation rates in placebo patients vary significantly. We conducted a meta‐analysis of the placebo response in vitiligo trials. Overall, repigmentation rates in patients receiving placebo were 22%, ranging substantially from 0 to 60%. Repigmentation (>25%) was still relatively common for placebo (9.35%), but fell to 5% when >50% improvement was analyzed. Higher frequencies of placebo responses correlated with more repigmentation in the intervention groups. Facial vitiligo and sunlight exposure was linked to higher placebo responses. Roughly estimating the amount of improvement using quartiles (0–25, 25%–50%, 50%–75%, 75%–100% repigmentation) resulted in higher placebo rates compared to other assessment methods. In clinical studies with older patients, the ratio of placebo reactions to treatment responses was higher. This is likely because clinical trials with older patients reported less repigmentation after treatment than studies with younger patients. The percentual difference in affected body surface area during the study period ranged from 6.2% worsening to 17.6% improvement in the placebo groups. This high variability in placebo responses illustrates the need for standardized outcome measures and more head‐to‐head trials in vitiligo.

show abstract